Project Grant R43HD095351

Burst Diagnostics Inc. received a $301,299 Project Grant from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), awarded September 15, 2025, with completion targeted for August 31, 2026. The project, conducted in partnership with FemmeLoop, develops a multiplexed, quantitative point-of-care and at-home diagnostic test designed to measure four key hormones—estradiol (E2), progesterone (PG),...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $304,966 to Kompass Diagnostics Inc. aims to develop a portable, cost-effective diagnostic device that can rapidly detect multiple blood-based biomarkers. The key focus is on enabling rapid, quantitative measurement of reproductive hormones to support time-sensitive clinical decisions in fertility treatments. The research objectives include developing an integrated...

MFB Fertility Inc. received a $256,000 Small Business Innovation Research Phase I Project Grant from the National Science Foundation to develop an ovulation biosensor. The grant was awarded on February 15, 2021 with a completion date of October 31, 2021 under the NSF's Engineering program (CFDA #47.041). The Engineering program seeks to improve quality of life and economic strength through innovative engineering research and education. Funds will support MFB Fertility's work to create a...

PS-Fertility, Inc. received a $356,502 Small Business Innovation Research (SBIR) Phase I award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), effective September 15, 2025, through August 31, 2026. The company is developing PS-DETECT, a diagnostic assay designed to identify fertilization-competent sperm by measuring phosphatidylserine (PS) as a biomarker on viable sperm surfaces....

The National Institute of Justice awarded a $0.00 Project Grant to The Leland Stanford Junior University from January 2018 through December 2020 under the National Institute of Justice Research, Evaluation, and Development Project Grants program (CFDA 16.560). The grant funded the development of a confirmatory test for sperm in sexual assault samples using a microfluidic-integrated cell phone imaging system. Work included designing a chip to support ease of use, performance and manufacturability...

This National Science Foundation (NSF) Biological Sciences grant award provides $2,225,964 to the Georgia Tech Research Corporation (Georgia Tech) to develop a novel biosensing platform called "protocell communities" that can be used for rapid, low-cost medical diagnostics. The project aims to create a tool that can diagnose medical conditions by detecting and integrating multiple indicator molecules, addressing limitations of single-analyte diagnostics. The protocell technology uses...

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...

This Project Grant award, funded by the National Science Foundation (NSF) under the Computer and Information Science and Engineering (CFDA 47.070) program, supports the development of new diagnostic testing methods for Open Radio Access Network (O-RAN) systems, which are critical components of 5G and future mobile network infrastructure. The $200,000 award, effective October 1, 2024 through September 30, 2027, aims to create a systematic approach to mobile network diagnostic testing that...

This $550,000 Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development and validation of a non-invasive, multiplex blood test for the early detection of preeclampsia, a serious pregnancy complication. The project aims to advance the detection of vascular dysfunction, particularly preeclampsia, by optimizing a blood test that targets disease-inducing signaling proteins on the surface of...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Quarksen LLC provides funding to develop an affordable, point-of-care diagnostic device for detecting viral and non-viral sexually transmitted infections (STIs) such as chlamydia, gonorrhea, syphilis, HIV, hepatitis C, and trichomoniasis. The project aims to create a device with an array of sensors that can rapidly and accurately detect STI biomarkers from cervical...